Michael Keyoung

InxMed Biotechnology Nanjing Co., Ltd. is a clinical-stage biotech company established in 2018, dedicated to developing innovative therapies to overcome treatment resistance, especially anti PD-1/PD-L1 resistance. InxMed is based in Nanjing, China, and has teams located in Shanghai and Beijing, with hubs in San Francisco and Melbourne. The Chinese company's innovations are inspired by patients and driven by in-depth understanding of disease biology and pharmacology. InxMed has raised tens of millions of US dollars in series A round financing and has an integrated high-caliber research and clinical development team across China, the US, and Australia. The company has built a unique innovative pipeline through its own discovery research and development and collaborative research and development. The company was founded in 2018 by Fei Cao and Zai Qi Wang, with Zai Qi Wang serving as the CEO since then.

CBC Group (Singapore) Pte. Ltd.(CBC Group) is a private equity firm founded in 2014 by Wei Fu. The firm is headquartered in Singapore with additional offices in New York, Hong Kong, Shanghai and Beijing and is wholly owned by CBC Group Investment Management Ltd.

PT Kalbe Genexine Biologics is a clinical-stage biotech company based in Jakarta, Indonesia. The Indonesian company specializes in licensing novel biologics and biosimilars in oncology and high-specialty therapeutic areas, as well as contract manufacturing. The company was founded in 2016 and is backed by Kalbe and Genexine, as well as US private equity giant General. The CEO is Sie Djohan.

I-Mab Bio-tech (Tianjin) Co., Ltd. engages in the research and development of medicine and biological products. Its business activities include investment information consultation, and health information services. The company was founded on April 19, 2012 and is headquartered in Tianjin, China.

C-Bridge Capital LLC (C-Bridge Capital) is a venture capital subsidiary of CBC Group founded in 2019 by Fu Wei. The firm is headquartered in New York..

I-Mab Biopharma (Shanghai) Co., Ltd. engages in the development of biologics. It focuses on monoclonal antibodies or bi-specific antibodies in the areas of immuno-oncology and autoimmune diseases. The company was founded by Jingwu Zang in March 2017 and is headquartered in Shanghai, China.